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Abstract
The pathogenic yeast Candida glabrata is the second-most common cause of
candidiasis in humans after Candida albicans. Interestingly, C. glabrata is
phylogenetically closer to Saccharomyces cerevisiae than C. albicans. One important
virulence factor in C. glabrata is its inherent resistance to the azole class of antifungals,
necessitating the continued discovery of novel antifungal agents. Many antifungals target
ergosterol or ergosterol biosynthesis. In an attempt to look for new potential drug targets
in C. glabrata, homologues of the genes in S. cerevisiae that regulate the transcription of
phospholipid biosythesis (the inositol regulon) were examined. The S. cerevisiae inositol
regulon consists of a heterodimeric transcriptional activator encoded by the genes INO2
and INO4 and a repressor encoded by OPI1, none of which are essential. The most well
studied target of these genes is INO1, whose protein product converts glucose-6phosphate to inositol-1-phosphate for the synthesis of phosphatidylinositol in the absence
of inositol. Disruption of INO2 or INO4 blocks transcription of several phospholipid
biosynthetic genes including INO1, resulting in inositol auxotrophy. Disruption of OPI1
causes overproduction of INO1 and other genes. Surprisingly, it was found that CgOPI1
is essential for viability in C. glabrata. This was found to be true for strains in both the
BG2 and ATCC2001 backgrounds indicating that this is not just a strain-specific effect.
This is very different from S. cerevisiae, where the Scopi1∆ mutant grows robustly.
These results led to the hypothesis that the CgOPI1 gene is necessary for viability
because it causes overexpression of a target of the inositol regulon transcriptional
activator CgIno2p-CgIno4p. Experimental evidence suggests that this hypothesis is true.
iii

Disruption of CgINO2 or CgINO4 leads inositol auxotrophy due to the inability to
transcribe regulon targets such as CgINO1. The Cgopi1∆ mutant’s viability defect can be
rescued by disruption of the Cgino2∆ gene. The Cgopi1∆ Cgino2∆ double mutant is
viable in the absence of CgOPI1 on a plasmid. These results indicate that blocking the
expression of a gene that is activated by the inositol regulon can rescue the Cgopi1∆
mutant’s viability defect. Identification of this target will help elucidate the phenotype.
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Chapter I
Background and Introduction
Background of Candida glabrata and Candida spp.
The Candida genus consists of a heterogeneous group of about 200 yeast species.
Some Candida species are the causative agents of candidiasis, a disease with a wide
clinical spectrum that includes superficial infections of the oral and vaginal cavities as
well as systemic infections. Candidiasis in the form of oral thrush was first documented
as far back as the fourth century B.C. by Hippocrates and again in 1665 by the London
journalist, Samuel Pepys. The initial discovery of the thrush organism is credited to
Langenbeck in 1839 who mistook it for the causative agent of typhoid fever. This
organism eventually was recognized as a fungus and came to be known as Monilia
albicans before receiving its current connotation of Candida albicans [1-3].
Despite the size of the Candida genus, relatively few of its known species are of
any medical significance, and in the early twentieth century, only Candida albicans was
thought to be of clinical importance. It was not until the latter part of the twentieth
century that there was an increase in the isolation of previously nonpathogenic species
from sites of infection [2]. This accompanied a general rise in nosocomial candidiasis,
which was due to an increasing population of immunocompromised patients. The
contributing factors to this include growing numbers of patients hospitalized for acquired
immunodeficiency syndrome (AIDS) as well as medical advances such as intravenous
catheters and chemotherapeutic treatments, which allow longer survival for people with
otherwise fatal conditions. These patients are more susceptible to fungal infections [2, 4].

Also, the incidence of oral colonization well as the proportion of blood stream infections
caused by some non-albicans species such as C. glabrata increases with age [5, 6].
Candida species have become the most important cause of opportunistic mycoses
worldwide and currently rank fourth among causes of nosocomial bloodstream infections
[5]. Although historically considered nonpathogenic, Candida glabrata is increasingly
isolated in both bloodstream and mucosal infections. It is now commonly cited as second
only to C. albicans in causing both oral and invasive candidiasis and has been associated
with high mortality despite indications of low virulence [5-7]. Although C. albicans
currently is not being challenged for its position as the primary cause of invasive
candidiasis, the percentage of C. albicans isolates appears to be decreasing and is
accompanied by a rise in non-albicans species [5].
Candida glabrata was originally classified in the genus Torulopsis. The
distinguishing factor between the two genera was the ability of Candida to display hyphal
or pseudohyphal growth and the inability of Torulopsis to do so. It was proposed that the
two genera be merged in 1978, and this remained a controversy for several years before it
was finally shown in 1997 that the basis of this separation was inadequate [8]. Although
most species in the genus Candida do exist in both yeast and hyphal forms, C. glabrata
has not been demonstrated to form hyphae. It was eventually shown that C. glabrata
could undergo a morphological change by exhibiting pseudohyphal growth during
nitrogen starvation [9].
The genus Candida belongs to the Ascomycetes class of fungi. Several species
have been described to have teleomorphic forms; however, historically, species within
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the genus were considered to be asexual, including the pathogenic yeast, Candida
albicans [10]. In 1999 it was discovered that C. albicans contained a mating type-like
(MTL) locus, which is similar to the MAT locus of Saccharomyces cerevisiae [11].
Further study revealed that several genes involved in mating in S. cerevisiae have
orthologues in C. albicans [12]. Mating was eventually described for C. albicans
between strains of opposite mating types that had undergone a phenotypic switch from
white to opaque [13]. A sexual cycle has never been described in C. glabrata, but it does
have conserved sexual genes, including at least 31 homologues of genes that function in
meiosis in S. cerevisiae. Among these genes are those for α-factor as well as a putative
MTL locus; however, it lacks some genes that are necessary for mating including STE2
and STE3, to which α-factor and a-factor bind, and MFA1, which is need to make afactor. C. glabrata has two silent mating loci, MTL1 and MTL2, similar to HMR and
HML in S. cerevisiae, but similar loci appear to be absent from C. albicans [14]. C.
glabrata also undergoes phenotypic switching, and since this has been shown to be
necessary for C. albicans mating, there could potentially be a cryptic sexual cycle yet to
be elucidated in C. glabrata [13]. Interestingly, in yeasts that do have teleomorphic
forms, the asexual form is the one that is isolated from sites of infection, suggesting that
mating may be disadvantageous in pathogenicity [14].
Despite the clinical similarities between C. albicans and C. glabrata, the two
organisms are quite different phylogenetically, with haploid C. glabrata actually being
more closely related to Saccharomyces cerevisiae (Figure A.1). Orthologous proteins in
C. glabrata and S. cerevisiae have an average of 65% amino acid identity, and the 38.8%
3

G+C content of C. glabrata is similar to the 38.3% of S. cerevisiae [15]. This same
conclusion was drawn based on the homology of the 18S rRNA sequence [16]. C.
albicans along with various Candida species also have a genetic code alteration in which
they translate CTG codons as serine rather than leucine, but C. glabrata lacks this
reassignment of codon usage [17]. Another difference between the two species is the
inability of C. glabrata to assimilate any sugars other than glucose and trehalose, which
accompanies its high numbers of gene loss including those genes involved in the
metabolism of galactose, phosphate, nitrogen, and sulfur [10, 18].

Virulence Factors
C. albicans and C. glabrata differ in their known virulence factors, and C.
glabrata lacks several of the virulence factors that had been identified in C. albicans such
as the production of secreted proteases. Another virulence factor that C. albicans
possesses and C. glabrata lacks is its ability to undergo filamentation. These
morphological changes increase adherence and tissue invasion, and C. albicans can form
both pseudohyphae and hyphae, whereas there is no clinical evidence that C. glabrata
exhibits a change in morphology between the commensal and pathogenic forms, although
it does form pseudohyphae in vitro [7, 15].
The virulence factors C. glabrata does have include cell-associated proteases and
adhesins. The C. glabrata family of adhesions is discussed first. A mutant screen
revealed that deletion of the gene EPA1, or epithelial adhesion 1, significantly reduced
the adhesion of C. glabrata to human epithelial cells [19]. It has since been shown that
there is actually a large family of EPA genes (similar to the ALS family in C. albicans),
4

and at least two others of these, EPA6 and EPA7, are able to mediate adherence;
however, they are normally kept silent via subtelomeric silencing mediated by the RIF1
and SIR3 genes [20]. The silencing of the SIR genes and subsequent induction of EPA6
and EPA7 occurs as a result of the limitation of nicotinic acid (NA), for which C.
glabrata is an auxotroph. Because urine is NA-limiting, the EPA6 and EPA7 genes are
transcribed during urinary tract infections, and their expression in this environment may
also contribute to the colonization of catheters by C. glabrata [21].
The other potential virulence factor for C. glabrata is a family of GPI-linked
aspartyl proteases. These genes were called YPS because of their homology to a group of
genes by the same name in S. cerevisiae. In S. cerevisiae the YPS genes are involved in
cell wall remodeling, and a similar function is suspected in C. glabrata. They are
required for in vitro survival of C. glabrata during stationary phase or conditions of cell
wall stress. In addition, the C. glabrata YPS genes were shown to be necessary for
survival within macrophages, and this family of genes was identified because of its
upregulation upon internalization of C. glabrata by macrophages [22]. C. glabrata
proteases differ from those of other pathogenic Candida species in that they are not
secreted extracellularly. C. albicans has a family of secreted aspartyl proteases (SAP)
which are encoded by the genes SAP1-10. Several studies have correlated production of
these proteases with virulence in C. albicans. Although different from the YPS proteases
in C. glabrata, the SAP family does contain two genes, SAP 9 and SAP10 that encode
sequences for GPI proteins [23].
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Phospholipases could play a role in C. glabrata infections as well because of their
potential to compromise host cell membranes. Evidence for this mechanism of action has
been given in both fungal and non-fungal pathogens, including C. albicans.
Phospholipase activity was detected in several other Candida species; however, there was
significantly less production in non-albicans species compared to C. albicans.
Nevertheless, phospholipase B was secreted by C. glabrata [24].
Also important in the pathogenesis of C. glabrata is its resistance to several
antifungal drugs, particularly the azole antifungals. Azoles exist in two classes,
imidazoles and triazoles, and are the most frequently used antifungal agents due to
advantages such as selectivity and low toxicity. Their mode of action is to block the
biosynthetic pathway of ergosterol, the principle sterol in fungal membranes. This is
accomplished by inhibiting the essential enzyme product of the ERG11 gene, lanosterol
demethylase, the lack of which causes methylated sterols to replace ergosterol in the
plasma membrane [25]. C. glabrata circumvents this by several mechanisms, but among
the most important is the ability to transport drugs back out of the cell. In addition, C.
glabrata can take up ergosterol precursors such as cholesterol from the host [10].
Drug resistance is found in several Candida species, but C. glabrata is inherently
less susceptible to fluconazole than is C. albicans, having a minimal inhibitory
concentration inhibiting 50% of the yeast population investigated (MIC50) of 16µg/ml,
compared to 0.25µg/ml in C. albicans. An increase in the frequency of C. glabrata
isolates from patients with candidiasis has been associated with fluconazole prophylaxis.
Genes encoding multidrug transporters of the ABC transporter family were identified in
6

C. glabrata. Transcription of the gene, CgCDR1, named after a similar gene in C.
albicans, was increased in azole-resistant isolates of C. glabrata [26]. CgPdr1p is a
transcription factor that regulates expression of the transporter genes CgCDR1 and
CgCDR2. A CgPDR1 deletion will cause an increase in azole susceptibility, but gain of
function mutations in this gene actually have been shown to increase azole resistance as
well as the fitness of the organism, increasing its virulence [27].

Transcriptional Rewiring Among Yeasts
It is well accepted that C. glabrata and S. cerevisiae are very closely related
phylogenetically, and comparative study of these two species could provide insight into
why one is increasingly successful in causing infection and the other is nonpathogenic. It
is widely believed that a whole genome duplication occurred in the two species’ shared
lineage. C. glabrata is thought to have lost the duplicated genes at a faster rate than S.
cerevisiae [17, 18]. Interestingly, a number of transcription factors were retained in
duplicate in C. glabrata while only being single-copy in S. cerevisiae, and this has been
interpreted to suggest that S. cerevisiae may have a simpler transcriptional regulatory
network than other yeasts [28].
Transcriptional rewiring among ascomycetous yeasts is a topic that has garnered
recent attention after the publication of the genome sequences of many of these yeasts.
Transcription factors can acquire and lose binding sites relatively quickly, and this
flexibility could lead to the emergence of new phenotypes. One such study focused on
the transcriptional regulator, Mcm1, which has a wide range of functions. While binding
about 4% of the genes in S. cerevisiae, it has different interactions in Kluyveromyces
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lactis (a yeast commonly used in dairy production) and C. albicans, where it binds about
12% of the genes in both organisms. When comparing target genes for Mcm1
homologues in all three species, only about 13%-18% of these genes are shared in
common among them, so this regulator controls many different genes among the three
yeasts. However, the Mcm1p cofactor interactions appear to be better conserved, and
these authors suggest that while protein sequences remain fairly constant, their regulatory
network has diverged significantly [29].
Rewiring of the transcriptional network has also been linked to the differing
oxygen requirements between S. cerevisiae and C. albicans, with the former preferring
fermentation even in the presence of oxygen, and the latter being primarily aerobic. An
upstream regulatory sequence associated with genes required for rapid growth is
conserved in both species but is overrepresented in C. albicans in the genes encoding
mitochondrial ribosomal proteins. In S. cerevisiae, these genes are induced only during
environmental stress, suggesting that a change in gene expression could cause this
phenotypic difference [30].
A comparative analysis of whole-genome transcription profiles from S. cerevisiae
and C. albicans yielded different amounts of conservation among groups of genes
arranged into Gene Ontology (GO term) categories. Interestingly, one GO term that was
not conserved was “regulation of transcription [25].” Together, these studies imply that
alterations in gene transcription and in the regulators of gene transcription could drive
phenotypic divergence among species. There have previously been no published data
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regarding transcriptional rewiring between S. cerevisiae and C. glabrata; however, given
their close relationship, such a study could prove beneficial.

Phospholipid Biosynthesis in Saccharomyces cerevisiae
Genetic Control of Phospholipid Biosynthesis
I have found that a C. glabrata homologue of an S. cerevisiae transcriptional
regulator involved in this process is essential in C. glabrata. This led to further study of
phospholipid regulation in C. glabrata and specifically, the de novo pathway of
phosphatidylinositol biosynthesis. The S. cerevisiae phospholipid biosynthetic pathway
and transcriptional regulon have served as a guide in this work, so S. cerevisiae
phospholipid biosynthesis and regulation are described below.
Phospholipids are a major component of cellular membranes, but also play a
number of other roles in yeast cells, including signal transduction and cell surface
recognition. The major phospholipids found in S. cerevisiae are phosphatidylinositol
(PI), phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine
(PS). The pathways controlling their biosynthesis are both tightly regulated and
coordinated, which is evidenced in part by all of these phospholipids being either direct
or indirect products of the precursor phosphatidic acid (PA), which is metabolized to
form the phospholipid precursors, CDP-diacylglycerol (CDP-DAG) or diacylglycerol
(DAG) [31] (Figure A.2).
PE and PC can be synthesized from either of two pathways: the de novo pathway
or the salvage pathway, which is also referred to as the Kennedy pathway. The first step
9

in the de novo pathway is the synthesis of PS from CDP-DAG and free serine, which is
catalyzed by PS synthase, the product of the CHO1 gene. PS is then decarboxylated to
form PE by PS decarboxylase, which is encoded by the genes PSD1 and PSD2. PE
undergoes three methylation reactions to form phosphatidyl-monomethyl ethanolamine,
phosphatidyl-dimethyl ethanolamine, and finally PC. PE methyltransferase from the
CHO2 (PEM1) gene is involved in the first reaction, and phospholipid methyltransferase
from the OPI3 (PEM2) gene catalyzes the final two [32].
PE and PC can also be synthesized from exogenous ethanolamine and choline via
the Kennedy pathway when the enzymes from the de novo pathway are repressed. The
enzymes ethanolamine kinase and choline kinase encoded by the EKI1 and CKI1 genes,
respectively, are responsible for the phosphorylation of ethanolamine and choline.
Phosphoethanolamine and phosphocholine are then converted to CDP-ethanolamine and
CDP-choline, respectively, by cytidylyltransferases encoded by the ECT1 and PCT1
genes. The final step of this salvage pathway involves the formation of PE and PC
through a reaction of the products from the second step with DAG [33].
PI is synthesized by the enzyme PI-synthase encoded by the PIS1 gene, which
converts CDP-DAG and inositol to PI. This is a necessary reaction, and without it, the
cell cannot live, implying that PI is an essential component of the yeast cell. PI-synthase
appears to have constitutive activity independent of the availability of PI precursors and
this activity also does not change when cells enter stationary phase, in contrast to the
activities of PS-synthase and CDP-DAG synthase [32].
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Inositol for PI synthesis is derived from exogenous sources or is synthesized de
novo from glucose-6-phosphate. The first step of the de novo pathway of PI biosynthesis
is the conversion of glucose-6-phosphate to inositol-1-phosphate (I1P) by inositol-1phosphate synthase. This enzyme is the product of the INO1 gene. I1P is subsequently
dephosphorylated to inositol by inositol monophosphatase, encoded by the INM1 or
INM2 genes [34].
INO1 is a highly regulated gene that is repressed in the presence of inositol. Its
transcription is activated by a heterodimeric transcriptional activator consisting of Ino2p
and Ino4p [35]. In the presence of inositol, the transcriptional repressor Opi1p binds to
Ino2p and prevents transcription of INO1 [36]. OPI1 stands for over-producer of
inositol, as it was first identified among mutants that secreted inositol into the
surrounding media [37]. In an opi1 mutant, transcription of INO1 is constitutively
activated, causing inositol to be produced and excreted [38]. Cells having an ino1,
ino2, or ino4 mutation are inositol auxotrophs [39] (Figure A.3)
In the absence of inositol, Opi1p is inactivated by binding to Scs2p, an integral
membrane protein, and PA, both of which are in the ER. Inositol is the rate limiting
component in PI biosynthesis. The presence of inositol induces the consumption of the
phospholipid precursor, PA, resulting in the release of Opi1p from the ER and its
translocation to the nucleus, where it binds Ino2p [40]. Ino2p and Ino4p bind
constitutively to the promoter of INO1, and are localized to the nucleoplasm under these
repressing conditions. Dissociation of Opi1p from this complex under derepressing
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conditions results in the recruitment of INO1 to the nuclear membrane, where
transcription is activated [41].
The inositol regulon controls the expression of many of the enzymes involved in
phospholipid biosynthesis in response to extracellular inositol and choline levels. Genes
that respond to inositol and choline contain an upstream activating sequence (UAS INO) in
their promoters. This sequence, CATGTGAAAT, has a basic helix loop helix (bHLH)
binding site, which is essential for it to function as a UAS element and is required for the
Ino2p of the Ino2p-Ino4p heterodimer to bind to INO1. This UASINO is also involved in
the regulatory response to Opi1p. A systematic substitution of each base pair in the
UASINO element revealed that this sequence is necessary for optimal function [42].
UASINO is also found in other genes that are involved in phospholipid biosynthesis and
inositol-choline response including CHO1, CHO2, CPT1, EPT1, OPI3, PIS1, PSD1,
INO1, as well as INO2 and INO4 [43].
Coordinate regulation of Phospholipid Biosynthesis
Evidence exists for the coordinate regulation of phospholipids. CDP-DAG is
partitioned within the different phospholipid biosynthetic pathways depending on the
available precursors. The presence of exogenous inositol shifts the utilization of CDPDAG, causing it to be converted to PI at the expense of PS, PE, and PC via the de novo
pathway (Figure A.2). Moreover, inositol serves as an inhibitor of PS synthase, the
product of the CHO1 gene, also driving metabolism in favor of PI [44]. Conversely, a
higher concentration of PS synthase can cause CDP-DAG to be consumed, thus altering
the rate of PI synthesis [32].
12

The INO1 gene is the best studied and most highly expressed gene that is
regulated by the interaction of these pathways. The level of INO1 mRNA is repressed
when cells are grown in inositol-containing media. INO1 is further repressed by the
addition of choline to cells already growing in inositol; however the addition of choline
alone caused only a slight increase in the abundance of INO1 RNA [38]. Repression by
inositol is not limited to the products of INO1 and CHO1, and the activity of CDP-DAG
synthase, PS decarboxylase and the two N-methyltransferases have all been shown to be
reduced in the presence of inositol [45].
An opi1 mutant is known to synthesize INO1 constitutively and independently
of inositol and choline; however, this mutant also has a high level of CHO1, indicating
that OPI1 also affects the de novo aminophospholipid pathway. The phospholipid
composition of the opi1 mutant remains stable regardless of inositol and choline levels
compared to that of a wild type cell, which changes depending on the availability of
inositol and choline. In addition, the activity of the methyltransferases, which are
involved in the conversion of PE to PC, do not fluctuate with varying levels of inositol
and choline in an opi1 mutant, in contrast to the wild type, further indicating that OPI1
has a pleiotropic effect on phospholipid regulation [38, 46].
INO2 and INO4 are also considered to be pleiotropic in that the phospholipid
compositions of the ino2 and ino4 mutants have a lower proportion of PC with an
accumulation of the methylated intermediates involved in the synthesis of PC from PE.
This suggests that Ino2p and Ino4p are required for maximum expression of the
methyltransferases as they are required for derepression of Ino1p [47]. This inhibition of
13

the pathway that synthesizes PC in ino2 and ino4 mutants is coupled to an increase in
the PI composition of the cell. Similarly, cho1 mutants that cannot synthesize PS have
higher levels of PI, and ino1 mutants lacking exogenous inositol have increased PS.
While PI is able to substitute for PS in cho1 mutants, the ino1 mutants under
conditions of inositol starvation eventually die [32].
Phospholipid regulation has been shown to affect other cellular functions. A
recent study screened mutants having the Opi- phenotype, secreting inositol into the
growth medium in the absence of inositol and choline. Among the Opi- mutants were
genes involved in various processes other than phospholipid biosynthesis such as protein
processing and trafficking and the unfolded protein response (UPR) [48]. Inositol
regulation had previously been implicated in the UPR when the transcription factor
Hac1p, which promotes transcriptional activation of unfolded proteins, was demonstrated
to be involved with the dissociation of Opi1p from the Ino2p-Ino4p complex [41].
Another role for the OPI1 gene was recently determined that showed it to be
involved in the activation of FLO11, which encodes an adhesion protein. Opi1- mutant
S. cerevisiae strains were deficient for invasive growth and mat formation; however, the
mechanism of this regulation remains to be elucidated [49]. The various contributions of
OPI1 to the cell suggest that it is an important regulator. The fact that OPI1 has
homologues in other species, including the close-relative pathogen, C. glabrata, makes it
a good candidate for further study in this species, especially since OPI1 was shown to
affect an adhesin, and one of the virulence factors of pathogenic yeast species is their
ability to adhere to host tissues.
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On a wider scale, the OPI1 family of genes, which has homologues across many
fungal species, is gaining attention and becoming better studied in some species and is
being associated with different functions. Most recently, the OPI1 homologue in
Yarrowia lipolytica, YAS3, was determined to play a regulatory role in the transcription
of ALK1, a gene necessary for the oxidation of n-alkanes. Yas3p does not regulate the Y.
lipolytica INO1 homologue, but it does regulate ALK1 in a manner that reflects the
relationship of Opi1p, Ino2p, and Ino4p in S. cerevisiae. In particular, Yas3p is a
repressor of ALK1 that represses transcription by binding to the Yas2p component of the
Yas1p-Yas2p heterodimeric transcriptional activator. Yas1p and Yas2p are homologs of
Ino4p and Ino2p, respectively.
The sequence of Yas3p is diverged from that of Opi1p (Figure A.4A). In
particular, Yas3p lacks some domains that are important for Opi1p including the
polyglutamine tracts, which are often found in regulatory genes, and the two
phenylalanines in an acidic tract (FFAT), which allow Scs2p to bind. Yas3p also lacks
the Opi1-Sin3 interaction domain by which Opi1p contacts the pleiotropic repressor,
Sin3p. [50] (Figures A.4A and A.4B). Interestingly, the Opi1p homologue in Candida
albicans also lacks similar domains, and like Yas3p, it does not regulate CaINO1 in C.
albicans (Chen and Reynolds, unpublished data) (Fig A.3A).
Interestingly, the Opi1p homologue from the much more closely related C.
glabrata contains all of the important domains that are present in S. cerevisiae Opi1p
(Figures A.3A and A.3B). What is more, we show in this thesis that CgOpi1p also
regulates CgINO1, CgCHO1, CgCHO2, and inositol biosynthesis in a manner very
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similar to that found in S. cerevisiae. The surprising contrast is that despite this similarity,
CgOpi1p is essential in C. glabrata, whereas it is not required for viability in S.
cerevisiae. This finding is novel among the Opi1p homologuess, and CgOpi1p represents
the first member of the Opi1p family to control viability. CgOpi1p’s control of viability
may indicate transcriptional or even metabolic rewiring in C. glabrata compared to S.
cerevisiae. The work in this thesis project addresses the mechanism by which CgOpi1p
controls viability in this fungus.

Chapter II
The inositol regulon controls viability in Candida glabrata
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This chapter is a paper by the same name submitted for publication in the journal
Molecular Microbiology in 2009 by Emily K. Bethea, Todd B. Reynolds and Billy
Carver.
My contributions to this paper include (1) design of most of the yeast strains, plasmids,
and primers used in the study, (2) some experimental design, (3) performance of most of
the experiments, and (4) generation of most of the figures.
Abstract
Inositol is essential in eukaryotes, and must be imported or synthesized. Inositol
biosynthesis in Saccharomyces cerevisiae is controlled by three nonessential genes that
make up the inositol regulon: ScINO2 and ScINO4, which together encode a
heterodimeric transcriptional activator, and ScOPI1, which encodes a transcriptional
repressor. ScOpi1p inhibits the ScIno2-ScIno4p activator in response to extracellular
inositol levels. An important gene controlled by the inositol regulon is ScINO1, which
encodes inositol-3-phosphate synthase, a key enzyme in inositol biosynthesis. In the
pathogenic yeast Candida albicans, homologues of the S. cerevisiae inositol regulon
genes are “transcriptionally rewired”. Instead of regulating the CaINO1 gene, CaINO2
and CaINO4 regulate ribosomal genes. Another Candida species that is a prevalent cause
of infections is Candida glabrata; however, C. glabrata is phylogenetically more closely
related to S. cerevisiae than C. albicans. Experiments were designed to determine if C.
glabrata homologuess of the inositol regulon genes functioned similarly to S. cerevisiae
or are transcriptionally rewired. CgINO2, CgINO4, and CgOPI1 regulate CgINO1 in a
manner similar to that observed in S. cerevisiae. However, unlike in S. cerevisiae,
CgOPI1 is essential. Genetic data indicate that CgOPI1 is a repressor that affects
viability by regulating activation of a target of the inositol regulon.

17

Introduction
Fungi of the genus Candida are the most common cause of human fungal
infections and can lead to both mucosal and systemic infections [51]. Candida albicans
is the most common cause of these infections, but non-albicans Candida species are
increasingly associated with disease [52]. One of these non-albicans species, Candida
glabrata is now the second most common cause of both mucosal and systemic Candida
infections [15].
Phylogenetically, Candida glabrata is more closely related to the non-pathogenic
yeast Saccharomyces cerevisiae than most of the other common species of Candida
associated with human disease [15]. C. glabrata lacks a number of the virulence factors
associated with Candida pathogens such as secreted hydrolases and hyphal growth [15].
Despite this, C. glabrata is a growing challenge in clinical settings where it causes
mucosal infections and is associated with approximately 15% of all Candida-related
systemic bloodstream infections [53]. These observations are interesting in light of the
fact that C. glabrata is more closely related to S. cerevisiae, but it is still a pathogen
whereas S. cerevisiae is only very, very rarely associated with infection [54]. A clearer
understanding of how S. cerevisiae and C. glabrata differ from one another may help
shed light on why one is a significant human pathogen and the other is not.
A number of recent studies have shown that Candida albicans is transcriptionally
rewired compared to S. cerevisiae. For example, the genes encoding enzymes of the
Leloir pathway for galactose catabolism in S. cerevisiae are regulated by the ScGal4p
transcription factor. However, in C. albicans these genes are regulated by the
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transcription factor Cph1p, while the C. albicans CaGal4p homologue regulates TCA
cycle genes such as CaLAT1 [55]. Other examples of transcriptional rewiring between C.
albicans and S. cerevisiae include regulatory systems controlling mating type [56],
mitochondrial ribosomal genes [30], and de novo myo-inositol biosynthesis genes [57],
(Chen and Reynolds, unpublished data). Myo-inositol will be referred to as inositol
throughout the rest of this article.
Since there are several examples of transcriptional rewiring between these two
more distantly related yeasts (S. cerevisiae and C. albicans), it was of interest to
determine if similar rewiring is present between the more closely related yeasts C.
glabrata and S. cerevisiae. The Leloir enzymes for galactose metabolism are not present
in C. glabrata, and this yeast is unable to utilize galactose [58], so this pathway is
unavailable for comparison. Mating has never been described for C. glabrata, thus this
pathway is not useful for study either. In contrast to these pathways, the inositol regulon
appears to be an excellent pathway to compare between these two yeasts. The inositol
regulon is a very well studied transcriptional regulon in S. cerevisiae (reviewed in [43,
59]), and there are C. glabrata orthologs for both the transcription factors and targets of
the S. cerevisiae inositol regulon (see results and discussion).
The inositol regulon in S. cerevisiae has been well-described [43, 59], and
consists of three main transcription factors that regulate target gene expression in
response to extracellular inositol levels (Fig 1). The roles of each of these transcription
factors in controlling this regulon are described in more detail below. Transcriptional
targets of the inositol regulon include a number of phospholipid biosynthetic genes, but
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the most highly expressed and well-characterized of these targets is the Saccharomyces
cerevisiae INO1 (ScINO1) gene. ScINO1 encodes an enzyme that occupies the ratelimiting step in de novo inositol biosynthesis. Inositol is essential and is required for the
synthesis of phosphatidylinositol (PI) which is a precursor for several essential lipids
including inositol-phosphate signaling lipids, glycosylphosphatidylinositol (GPI) anchors,
and sphingolipids [60] [61].
ScIno1p is an inositol-3-phosphate synthase which converts glucose-6-phosphate
to inositol-3-phosphate [62]. Inositol-3-phosphate is dephosphorylated by the inositol
monophosphatases ScInm1p or ScInm2p to create inositol [34]. An Scino1∆ mutant
cannot make inositol de novo and is an inositol auxotroph. In the absence of extracellular
inositol (or at low concentrations like 10µM) ScINO1 is expressed, and in the presence of
higher concentrations of extracellular inositol ScINO1 is repressed [63] (Fig 1).
The inositol regulon transcription factors ScIno2p and ScIno4p form a
heterodimeric transcriptional activator that binds to the upstream activator sequence
(UASINO) in the promoters of target genes such as ScINO1 [35, 42, 64-66]. Both ScIno2p
and ScIno4p are absolutely required for transcription of ScINO1, so Scino2∆ and Scino4∆
mutants are inositol auxotrophs.
The regulation of ScINO1 in response to extracellular inositol is dependent on the
repressor protein ScOpi1p [40, 67-70]. ScOpi1p senses the level of extracellular inositol
indirectly based on the level of the PI precursor lipid phosphatidic acid (PA). Inositol is
the rate-limiting metabolite in PI synthesis, and when there is abundant extracellular
inositol, PI synthesis is maximal, and PA levels are lower because PA is consumed
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during synthesis of PI. In these conditions ScOpi1p binds to ScIno2p and represses
transcription of ScINO1. When extracellular inositol is not available or is greatly
decreased, PI synthesis slows, and PA levels increase in the endoplasmic reticulum (ER).
ScOpi1p, which binds to PA, is recruited to ER where it binds PA and the ER protein
Scs2p. Thus, the ScIno2p-ScIno4p heterodimer is free to transcribe ScINO1. A mutation
that deletes ScOPI1 results in constitutive overexpression of ScINO1 and of other genes
carrying the UASINO sequence in their promoters.
The purpose of this study was to determine if C. glabrata carried an inositol
regulon that is similar to that in S. cerevisiae, or if these yeasts are transcriptionally
rewired for inositol regulation. In order to do this, C. glabrata homologues of the S.
cerevisiae inositol regulon proteins were identified and disrupted. Analysis of these
mutants revealed the surprising finding that CgOPI1 is essential for growth under the
experimental conditions used in this study. CgIno2p and CgIno4p (which are not
essential) are activators of CgINO1, and CgOpi1p is a transcriptional repressor of
CgINO1, like the situation in S. cerevisiae. However, unlike in S. cerevisiae, CgOPI1 is
required for viability. This difference from S. cerevisiae may indicate that the inositol
regulon in C. glabrata has some additional or different targets than bakers’ yeast, or C.
glabrata may be metabolically rewired compared to S. cerevisiae.

Results
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CgINO2 and CgINO4 encode transcriptional activators of the CgINO1 gene and
control de novo inositol biosynthesis
A homologue of ScINO1 was identified in C. glabrata by BLASTing the ScINO1
translated protein sequence against the Candida glabrata genome at the Genolevures
website (http://cbi.labri.fr/Genolevures/elt/CAGL). The BLAST search revealed that the
gene CAGL0I06050g encoded a protein that was 73.9% identical to ScIno1p. We refer to
CAGL0I06050g as CgINO1 based on the experiments described below.
CgINO1 expression was examined in media containing or lacking inositol by
Northern blotting which revealed that CgINO1 was highly expressed in medium lacking
inositol, but it was not expressed in medium containing 75µM inositol (Fig 3). This is
similar to what has been observed for ScINO1 in S. cerevisiae [19, 63, 71]. In order to
determine if CgINO1 was required for de novo inositol biosynthesis, the CgINO1 open
reading frame (ORF) was disrupted by homologous recombination using a two-step gene
deletion strategy (Supplemental figure 1 and methods and materials) [19, 71]. The
resulting Cgino1∆ mutant was unable to grow on inositol-free medium (Fig 2). However,
when the CgINO1 gene was reintegrated into the genome at the CgINO1 locus, the
reconstituted strain (Cgino1∆::CgINO1) could grow in medium lacking inositol (Fig 2).
The CgINO1 gene is regulated in a similar manner as the ScINO1 gene in
synthetic medium containing or lacking inositol which suggested that the inositol regulon
that controls ScINO1 in S. cerevisiae might be conserved in C. glabrata. In order to test
this, homologues of the ScINO2 and ScINO4 transcriptional activator genes were
identified by BLAST searches querying the protein sequences of ScIno2p and ScIno4p
against the C. glabrata genome at the Genolevures website
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(http://cbi.labri.fr/Genolevures/elt/CAGL). The BLAST searches revealed only one
strong homologue for each protein, and these were encoded by the genes
CAGL0B01947g for ScIno2p (35.6% identity) and CAGL0I07359g for ScIno4p (44.5%
identity). These genes, CAGL0B01947g and CAGL0I07359g, were named CgINO2 and
CgINO4, respectively. CgINO2 and CgINO4 were disrupted using the two-step gene
disruption method which completely removed the ORF of each gene. The resulting
Cgino2∆ and Cgino4∆ mutants were tested to determine if they could grow in the
absence of inositol in the medium. As seen for orthologous Saccharomyces mutants, the
Cgino2∆ and Cgino4∆ mutants were unable to grow on inositol-free medium (Fig 2).
These data suggested that CgINO2 and CgINO4 controlled the expression of the CgINO1
gene. Northern blotting revealed that Cgino2∆ and Cgino4∆ mutants showed a complete
lack of CgINO1 expression even in inositol-free medium (Figure 3). Reconstituted
Cgino2∆::CgINO2 and Cgino4∆::CgINO4 strains, conversely, grew well on medium
lacking inositol (Fig 2) and regulated CgINO1 much like the wild-type strain (Fig 3).

CgOPI1 encodes an essential gene in Candida glabrata
In S. cerevisiae the ScOPI1 gene encodes the main regulator of de novo inositol
biosynthesis in Saccharomyces, and its homologue was identified in a BLAST search
against the C. glabrata genome at Genolevures as described above. The protein encoded
by CAGL0K03267g was found to be 52.3% identical to ScOpi1p. An attempt was made
to disrupt the CgOPI1 gene by the two-step gene disruption strategy; however, this
method continuously yielded strains carrying a wild-type ORF of CgOPI1.
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The above results suggested that CgOPI1 might be essential. This was tested by
the strategy described in figure 4. The CgOPI1 gene along with non-coding DNA
flanking both 5’ and 3’ of the ORF (including the transcriptional promoter and
terminator, respectively) were cloned into the single-copy CEN/ARS vector pGRB2.1
[72], which is marked with the S. cerevisiae URA3 gene, to create the plasmid pCgOPI1.
The pCgOPI1 plasmid was transformed into the wild-type strain, and the chromosomal
CgOPI1 ORF was disrupted by homologous recombination using the construct described
in figure 4 that contains the nourseothricin resistance marker NAT1 [73]. The resulting
pCgOPI1 Cgopi1∆ strain was then streaked onto medium containing 5-fluoroorotic acid
(5-FOA). Processing of 5-FOA by the URA3 gene product from S. cerevisiae or C.
glabrata leads to production of 5-fluorodeoxyuridine which is toxic to C.glabrata [71,
74].
If the Cgopi1∆ mutation is lethal, then no Cgopi1∆ pCgOPI1 colonies should
grow on 5-FOA medium because the 5-FOA would select against the cells carrying
pCgOPI1. In figure 5 it is clear that the Cgopi1∆ pCgOPI1 strain cannot grow on 5-FOA.
In contrast, the parental strain carrying either pCgOPI1 or the empty vector grew well on
this medium.
These experiments were performed in the strain background BG2 [71], and there
was concern that this phenotype was strain-specific. In order to rule this out, the above
strategy was used to test the essentiality of CgOPI1 in the strain background ATCC 2001
(a gift from Karl Kuchler). It was found that CgOPI1 was essential in the ATCC 2001
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strain as well, which suggested that the essentiality of CgOPI1 is not just a BG2 strainspecific phenomenon (data not shown).

The regulation of viability by CgOPI1 is dependent on the CgINO2 transcription
factor
Based on the model from S. cerevisiae (Fig 1), it was hypothesized that disruption
of CgOPI1 causes overexpression of a downstream target of the inositol regulon that then
results in a loss of viability. In S. cerevisiae, overexpression of ScINO1 in the Scopi1∆
mutant is due to unrepressed transcriptional activation by ScIno2p (Fig 1). The Scopi1∆
mutant’s ScINO1 overexpression phenotype can be blocked by a Scino2∆ mutation. The
Scopi1∆ Scino2∆ double mutant acts like the Scino2∆ single mutant and fails to express
ScINO1 because the Scino2∆ mutation is epistatic to the Scopi1∆ mutation [63].
If the Cgopi1∆ mutant compromises viability due to overexpression of a
downstream target of CgIno2p, then a Cgino2∆ mutation should restore the viability of a
Cgopi1∆ mutant by blocking expression of this putative target. In order to test this
hypothesis, the Cgino2∆ mutant was transformed with the pCgOPI1 plasmid, and the
chromosomal ORF of CgOPI1 was disrupted as described (Figure 4). The resulting
Cgopi1∆ Cgino2∆ pCgOPI1 strain was streaked on 5-FOA medium, and it was found to
grow like the wild-type strain carrying pCgOPI1 or empty vector (Fig 6). The Cgino2∆
strain also grew like wild-type (Fig 6).
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The CgOPI1 gene product represses expression of CgINO1
The results above suggest that CgOPI1 can act as a repressor of CgINO2 targets
such as CgINO1. In order to determine if CgOPI1 could repress CgINO1, CgOPI1 was
place under the control of a doxycycline repressible promoter [75]. The C. glabrata
BG14 strain (Cgura3∆) was modified by disrupting both the CgHIS3 gene (making it a
histidine auxotroph) and the CgTRP1 gene (making it a tryptophan auxotroph). Using the
resulting triple auxotroph (Cgura3∆ Cghis3∆ Cgtrp1∆), the promoter of the CgOPI1
gene was replaced on the chromosome by homologous recombination with the tetOHOP1 promoter construct derived from plasmid p97CGH (CgHIS3) [75]. This strain was
further modified by integration of the pINTG4 plasmid (CgTRP1) carrying the
tetR::GAL4AD repressor-activator that activates the tetO-HOP1 chimeric promoter in the
absence of doxycycline, but represses it in the presence of doxycycline.
The resulting strain was then tested for growth in the presence and absence of
doxycycline, and it was found that this strain showed very poor growth in 10µg/ml
doxycycline, but grew quite well in the absence of doxycycline (Fig 7B). These
experiments were performed on synthetic minimal medium, but similar results were seen
in YPD (rich) medium (E. Bethea and T. B. Reynolds, data not shown). When CgOPI1
levels were assessed in this strain by Northern blot, it was found that CgOPI1 was
expressed in the absence of doxycycline, but was not expressed in the presence of drug
(Fig 7A).
CgOpi1p acts as a repressor of CgINO1 expression as measured by Northern
blotting. It was found that when CgOPI1 expression is repressed by doxycycline,
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CgINO1 expression increases substantially, but when CgOPI1 is expressed in the absence
of doxycycline, then CgINO1 expression is very low or undetectable (Fig 7A). This
indicates that CgOpi1p acts as a repressor of CgINO1. We were also able to demonstrate
the regulation of CgINO1 expression by CgOpi1p using the C. glabrata copper-inducible
MTII promoter [76] as well (E. Bethea and T. B. Reynolds, data not shown).

Overexpression of CgINO1 is not responsible for the loss of viability in the Cgopi1∆
mutant
Since CgINO1 is overexpressed in the absence of CgOPI1, it seemed possible that
CgINO1 overexpression is responsible for the loss of viability. This was tested by
creating a Cgopi1∆ Cgino1∆ pCgOPI1 double mutant. However, when this double
mutant is streaked onto 5-FOA it fails to grow (data not shown) indicating that the
disruption of CgINO1 is not sufficient to restore viability as seen with CgINO2 (Fig 6).

CgCHO1 and CgOPI3 show altered gene expression in the CgOPI1-tetO strain
Genes that respond to inositol and choline in S. cerevisiae have an upstream
activating sequence in their promoters called the UASINO. This sequence is found in
OPI1 as well as INO2, INO4, and INO1. It is also found in five genes in C. glabrata,
including CgCHO1, CgOPI3, CgCHO2, CgINO1, and CgITR2. A northern blot analysis
was performed using the strain containing the CgOPI1-tetO fusion in order to see if these
two genes might be influenced by CgOPI1. It was found that under conditions of
CgOPI1 repression, both CgCHO1 and CgOPI3 showed increased expression (Fig 9).
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Discussion
Transcriptional rewiring has been suggested between the inositol regulons of S.
cerevisiae and C. albicans, based on the observations that CaINO2 and CaINO4 genes
cannot regulate the CaINO1 gene in a heterologous expression system in S. cerevisiae
[57]. In addition, the CaIno2p and CaIno4p proteins do not appear to bind to the CaINO1
promoter, which contrasts with ScIno2p and ScIno4p that bind the ScINO1 promoter.
Interestingly, the CaIno2p-CaIno4p complex appears to bind to a sequence in the
promoters of several rRNA genes in C. albicans. It has even been suggested that CaINO2
and CaINO4 are essential in C. albicans based on the fact that only heterozygous mutants
could be made. However, this result is not definitive as a conditional promoter was not
used to confirm these assertions. Additional support for the hypothesis that the inositol
regulon in C. albicans is rewired compared to S. cerevisiae is provided by the fact that
the CaOPI1 gene does not affect the expression of CaINO1 (Chen and Reynolds,
manuscript in preparation).
Candida glabrata is much more closely related to S. cerevisiae than C. albicans
based on phylogenetic trees comparing 18S ribosomal sequences [15]. Our analysis
suggests that the C. glabrata inositol regulon is not transcriptionally rewired compared to
S. cerevisiae, at least for CgINO1 regulation. However, a major difference between the
two species is that the OPI1 homologue in C. glabrata appears to be essential, whereas it
is not for S. cerevisiae. This result suggests that there are important differences between
S. cerevisiae either in downstream targets of the Opi1p homologues or in the lipid
metabolism of these fungi.
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BLAST searches against the C. glabrata genome revealed that it contained
homologues of the S. cerevisiae inositol regulon components and the ScINO1 gene. Gene
disruption studies revealed that the CgINO1 gene is required for de novo inositol
biosynthesis indicating that it is the C. glabrata inositol-3-phosphate synthase gene (Fig
2). CgINO2 and CgINO4 encode orthologs of the S. cerevisiae inositol regulon
components as they are required for CgINO1 transcription and de novo inositol
biosynthesis (Figs 2 and 3). When the expression of the CgOPI1 gene was repressed
using the doxycycline repressible promoter system, the CgINO1 gene was overexpressed
compared to the wild-type strain, indicating that CgOpi1p is a transcriptional repressor of
CgINO1 (Fig 7A).
The most interesting observation, however, was that CgOPI1 appears to be
essential for viability. Reduction of expression of the CgOPI1 gene using the
doxycycline repressible promoter prevented growth on solid agar medium (Fig 7) and
decreased growth in liquid medium (data not shown).
It is not clear how CgOpi1p controls viability, but our data suggest that it causes a
loss of viability by overexpressing a downstream target of CgIno2p-CgIno4p. We found
that a mutation of CgINO2 can rescue the Cgopi1∆ mutant’s viability defect (Fig 6).
A model to explain this rescue of viability by the Cgino2∆ mutation is derived
from the inositol regulon in S. cerevisae. The ScINO2 gene has been shown to be
epistatic to ScOPI1 for the regulation of ScINO1 and inositol biosynthesis [63]. The
Scopi1∆ mutant overexpresses ScINO1 and the Scino2∆ mutant fails to express ScINO1.
The Scopi1∆ Scino2∆ double mutant behaves like the Scino2∆ single mutant and fails to
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express ScINO1. ScOpi1p is the primary regulator of this regulon, and in a Scopi1∆
mutant the ScIno2p-ScIno4p complex constitutively activates target genes resulting in
overexpression of ScINO1. ScIno2p is absolutely required for target gene expression,
thus a Scino2∆ disruption blocks ScINO1 expression even if ScOPI1 is disrupted.
Using this model as a guide, it would appear that the Cgopi1∆ mutation causes
overexpression of CgIno2p target genes and one of these targets causes a loss in viability
when overexpressed. Disruption of CgINO2 in the Cgopi1∆ strain rescues growth of the
Cgopi1∆ mutant because the downstream target is no longer overexpressed.
One possible target appeared to be CgINO1, however disruption of CgINO1 in the
Cgopi1∆ strain did not rescue viability on 5-FOA plates indicating that CgINO1
overexpression is not toxic.
There are two main models to explain the Cgopi1∆ mutant’s loss of viability. 1)
A direct downstream target gene involved in phospholipid biosynthesis is overexpressed,
and C. glabrata is particularly sensitive to this imbalance in lipid biosynthesis and loses
viability. 2) Expression of a direct target gene not involved in lipid biosynthesis is
affected by Cgopi1∆ and results in a loss of viability.
In the first model, there are several phospholipid biosynthetic genes that may be
targets of the C. glabrata inositol regulon based on sequence similarity to homologues in
S. cerevisiae. Direct downstream targets of the S. cerevisiae inositol regulon have been
identified by the presence of the UASINO consensus sequence CATGTGAAAT in their
promoters and their misregulation in Scino2∆, Scino4∆, and Scopi1∆ mutants [63, 77-80].
Using these genes as a guide, there are five genes in C. glabrata that contain the sequence
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CATGTG (the most important part of the UASINO consensus sequence [43]) in their
promoters. These genes include CgINO1, CgOPI3, CgCHO1, CgCHO2, and CgITR2. In
addition to these five genes, two other genes, CgERG20 and CgCKI1, contain the
sequence CATGTT, which differs by only one base and could possibly also respond to
the inositol regulon. Preliminary data involving CgOPI3 and CgCHO1 (Fig 9) indicate
that this model could be correct; however, further experiments including the creation of
double-knockout strains of CgOPI1 and each of these genes must be performed to
provide support for this hypothesis.
In the second model, the target may be unrelated to phospholipid biosynthesis
and/or may not have a homologue that is regulated by the inositol regulon in S.
cerevisiae. Such a gene might also not be the direct cause of the loss of viability, but
might itself regulate a downstream effector and cause the loss of viability. For example,
if CgOPI1 were to repress a transcriptional repressor of an essential gene then loss of
CgOPI1 could result in loss of expression of the essential gene and compromise viability.
We are currently investigating these different possibilities in order to elucidate the
mechanism by which CgOPI1 controls viability in C. glabrata.
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Experimental Procedures
Strains and media
Strains are listed in Table 1. Integrations and manipulations were confirmed by
PCR (Table 2) in most cases and by Southern blotting with the tetO::HOP1::CgOPI1
strain. The BG14 strain, which is a uracil auxotroph (Table 1), was a gift from Brendan
Cormack and was used to generate all of the strains reported in this study. Disruption of
CgINO2, CgINO4, and CgINO1 was performed in BG14 (Table 1) utilizing the two-step
gene disruption strategy [19, 71, 81] with disruption constructs built in the pRS306 vector
[82] (Table 3) carrying the ScURA3 marker that can be selected for on media lacking
uracil and counter-selected against using media containing 5-FOA (supplemental figure
1). Reintgrates of each of these gene disruption mutants were made by transforming the
strains with ScURA3-marked integrating plasmids carrying the wild-type gene (Table 3).
The Cgopi1∆ mutant (Table 1) was generated in BG14 by transforming it with the
pCgOPI1 episomal plasmid (ScURA3 marker, Table 3), and then disrupting the CgOPI1
gene with the Cgopi1::NAT1 construct amplified from plasmid pCgopi1∆ (Table 3). The
Cgopi1∆ Cgino2∆ double mutant was made in the same manner as the Cgopi1∆ mutant
except it was done in the Cg5 (Cgino2∆) strain.
The tetO::HOP1::CgOPI1 strain EBCg048 (Table 1) was generated by first
making BG14 a histidine and tryptophan auxtotroph (Cghis3∆ Cgtrp1∆). This was done
by disrupting CgHIS3 in BG14 as described above for the Cgino2∆ gene to create the
Cg33 strain. The CgTRP1 gene was disrupted in Cg33 using a plasmid from Karl
Kuchler’s lab to create strain EBCg046. EBCg046 was used to create the
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tetO::HOPI1::CgOPI1 strain EBCg048 by first integrating the pINTG4 plasmid carrying
the tetR::GAL4AD repressor-activator into its genome as described [75]. Then the
tetO::HOP1::CgOPI1 construct was PCR amplified from plasmid pEB48 (Table 3) and
was used to replace the CgOPI1 locus on the chromosome.
Media used in this study included 2% agar plates or liquid medium made with
YPD, YNB, or inositol free media [83] with the supplements of amino acids, nucleotides,
inositol, doxycycline, 5-fluororotic acid (5-FOA), etc as described in the text. For
inositol-free media Bactoagar was used because it does not contain trace amounts of
inositol.

Plasmids and constructs
The gene disruption plasmids (pRS306-ino2∆, pRS306-ino4∆, and pRS306ino1∆) were made by PCR amplifying DNA corresponding to approximately 500
basepairs of noncoding DNA that flanked the 5’ and 3’ edges of each open reading frame
(5’ or 3’-NCRs), and then cloning them into pRS306 adjacent to one another to create a
disrupted allele (primers and restriction sites used for cloning are listed in Table 2). The
pRS306-his3∆ disruption plasmid was created in a similar manner by subcloning the
CgHIS3 5’-NCR into the plasmid pGRB2.1 [72] upstream of the 3’NCR of CgHIS3
contained in this plasmid. The whole 5’ and 3’-NCR disruption cassette was then
subcloned into the pRS306 integrating vector [82] as an XbaI-KpnI fragment to create
pRS306-his3∆. The disrupted alleles from all of the pRS306 disruption cassette
plasmids were used to replace the respective wild-type alleles on the chromosome of
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BG14 by the two-step deletion strategy [19, 71, 81]. For example, the pRS306-ino1∆
cassette was cut with NruI in the 5’-NCR to linearize it and target it to recombine
upstream of CgINO1 (Figure 7). PCR was used to confirm correct integration, and
disruption. In a similar manner, the pRS306-ino4∆, pRS306-ino1∆, and pRS306-his3∆
plasmids were cut with PmlI, SnaBI and BglII respectively. Following replacement of
the wild-type genes with the disrupted alleles, the mutant alleles were confirmed based on
phenotype and PCR. Reintegration constructs were generated for each of the above
disruptants in the vector pRS306 by PCR amplifying the corresponding ORFs plus ~500
basepair 5’ and 3’-NCRs with the primers BCO3 and BCO2 for CgINO2, USO1 and
USO4 for CgINO4, and MHO3 and MHO2 for CgINO1. Cut sites for subcloning are
listed in Table 2. Plasmids were linearized with the enzymes sites mentioned above, and
transformed into their respective disruptant strains. Correct integrations were confirmed
by PCR with primers listed in Table 2.
The episomal pCgOPI1 plasmid carrying CgOPI1 plus 215 basepairs of upstream
DNA and 439 basepairs of downstream DNA was generated by amplifying the CgOPI1
ORF and flanking sequences from purified BG14 DNA using primers TRO605 and
TRO608, and cutting the PCR product with BamHI and SpeI enzymes. The SpeI site was
introduced by primer TRO608 and the BamHI site was internal to the amplified DNA
fragment. This PCR product was cloned into the ScURA3 bearing C. glabrata CEN/ARS
plasmid pGRB2.1 [72] using SpeI and BamHI. The Cgopi1∆ plasmid was generated by
subcloning the NAT1 cassette from pAG25 [73] with primers TRO652 and TRO653 into
an EcoRI site between a 469 basepair fragment containing the 5’-NCR of CgOPI1
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(cloned in by primers TRO605 and TRO606) and a 439 basepair fragment containing the
3’-NCR of CgOPI1 (cloned in by primers TRO607 and TRO608) both carried on the
pRS306 vector. The pINT4 vector was a gift from Hironobu Nakayama [75] and was
integrated into the EBCg046 genome after cutting it with EcoRV [75]. The pEB48
plasmid was generated by subcloning an ~500 basepair 5’-NCR of the CgOPI1 ORF into
p97CGH upstream (5’) of the HIS3 tetO-HOP1 cassette using primers EBO76 and
EBO77. The CgOPI1 ORF was then subcloned 3’ to the HIS3 tetO-HOP1 cassette using
a PCR product made by primers EBO64 and EBO65. This whole segment from pEB48
containing 5’-CgOPI1 promoter-HIS3 tetO-HOP1-CgOPI1 ORF was then transformed
into the EBCg046 strain carrying pINTG4 to replace the CgOPI1 promoter with the tetOHOP1 cassette.

Northern blotting
Northern blotting was performed essentially as described [49] using probes
generated from primers EBO40 and EBO41 for CgINO1, EBO11 and EBO12 for
CgOPI1, TRO656 and TRO636 for CgACT1, EBO56 and EBO57 for CgCHO1, EBO54
and EBO55 for CgOPI3, and EBO58 and EBO59 for CgCHO2.
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Appendix 1: Tables
Table 1. Strains used in this study
Strains
Genotype
BG14
Cgura3::Tn903neoR
Cg11
Cgura3::Tn903neoR pCgOPI1
Cg12
Cgura3::Tn903neoR pGRB2.1
Cg14
Cgura3::Tn903neoR Cgopi1∆ pCgOPI1
Cg5
Cgura3::Tn903neoR Cgino2∆
EBCg019 Cgura3::Tn903neoR Cgino2::CgINO2
Cg23
Cgura3::Tn903neoR Cgino2∆ pCgOPI1
Cg18
Cgura3::Tn903neoR Cgino2∆ Cgopi1∆ pCgOPI1
EBCg005 Cgura3::Tn903neoR Cgino4
EBCg008 Cgura3::Tn903neoR Cgino4::CgINO4
EBCg014 Cgura3::Tn903neoR Cgino1
EBCg017 Cgura3::Tn903neoR Cgino1::CgINO1
Cg33
Cgura3::Tn903neoR Cghis3∆
EBCg046 Cgura3::Tn903neoR Cghis3 Cgtrp1∆
EBCg048 Cgura3::Tn903neoR Cghis3 Cgtrp1∆ pINTG4 pEB48
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Reference
[71]
This study

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Table 2. Primers used in this study
Primer

Sequence
a

TRO605
TRO606
TRO607
TRO608
TRO652
TRO653
VSO1
VSO2
VSO3
VSO4
MHO3
MHO4
MHO1
MHO2
BCO3
BCO4
BCO1
BCO2
TRO665
TRO667
EBO24
EBO27
TRO668
TRO623
TRO536

AAAAAAGCTTTGCCTCCTTATCGGTAACAA
AAAAGAATTCTCCAGCAGCACAGTTTATTCA
AAAAGAATTCCTCTTCAAATTGAAAACGTTACGAC
AAAAACTAGTGATTTCTGTTTGACTATTGGTTCTC
AAAAGAATTCCAGCTGAAGCTTCGTACGC
AAAAGAATTCGCATAGGCCACTAGTGGATCTG
AAAACTCGAGCCTTTACACCTGTGAACTACAGTCA
AAAAGAATTCTCCGACTTTTGAAATGGGGT
AAAAGAATTCTGCCTGTAATTGAGAAATCCTATTG
AAAAGGATCCTTGAAAAGAGAAGTTAAAACAGAGG
AAAACTCGAGTGTCCCCTTTTTTTTTGCC
AAAACCCGGGTCGTGTGGTAAGTGTAGTTGGTCA
AAAACCCGGGCAGACTTCCCAATGAGGGAAA
AAAACCGCGGCGTTCGTTGGCGAAACTTTT
AAAAAAGCTTTCGCCCGTCTGAAAAAAA
AAAAGAATTCGGTTCGTGTATTAAATTAAGCACTC
AAAAGAATTCCTACTGACTGTATGTTAGGCTGCAA
AAAAGGATCCCAAACTCTTCTTTGAATGACTTTG
AAAATCTAGAATTCCCCCATGTACCACAGTC
AAAAGGATCCTTGCTCGATGCTTCTCTTTG
GTTGCTGTTAAGTATGTTTGA
TGGCAACTAGAATTTTTCACATGC
TACGTTGTTACCCACACGATT
ACAGTCATCCAAAGGTGACTCTCAT
CCAGGGTTTTCCCAGTCA

TRO614
TRO461

GAAGGAATCTCAAAAGTGCGGA
GTGCGCAGAAAGTAATATC

EBO64
EBO 65
EBO40
EBO41
TRO656
TRO636
EBO12
EBO11

AAAAGAATTCACCATGGACACAAGGCGTG
AAAAGGGCCCGTAGATGTAGGTTCTCCTTTTCATTA
ATGACTGTGAATAAAGGTATTAGCATTC
CTATTTCAATCTTTCTTCGAATCTCAG
GCCGGTTTCGCCGGTGACG
CCAAAGCGACGTAACATAGCTTT
GACACAAGGCGTGGGTG
TCATACCTTTTGTAAATGCATA

Restriction
site
HindIII
EcoRI
EcoRI
SpeI
EcoRI
EcoRI
Xho1
EcoR1
EcoR1
BamH1
Xho1
Sma1
Sma1
SacII
HindIII
EcoR1
EcoR1
BamH1
XbaI
BamHI

Purpose

EcoR1
Apa1

Forward for CgOPI1 tetO promoter
Reverse for CgOPI1 tetO promoter
Forward for CgINO1 probe
Reverse for CgINO1 probe
Forward for CgACT1 probe
Reverse for CgACT1 probe
Forward for CgOPI1 probe
Reverse for CgOPI1 probe

a Underline shows the restriction site
b NCR-non-coding region that is either 5’ or 3’ to the designated ORF
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Forward for 5’NCRb of CgOPI1l
Reverse for 5’NCR of CgOPI1l
Forward for 3’NCR of CgOPI1l
Reverse for 3’NCR of CgOPI1l
Forward for NAT1 gene
Reverse for NAT1 gene
Forward for 5’ NCR CgINO4
Reverse for 5’ NCR CgINO4
Forward for 3’ NCR CgINO4
Reverse for 3’ NCR CgINO4
Forward for 5’ NCR CgINO1
Reverse for 5’ NCR CgINO1
Forward for 3’ NCR CgINO1
Reverse for 3’ NCR CgINO1
Forward for 5’ NCR of CgINO2
Reverse for 5’ NCR of CgINO2
Forward for 3’ NCR of CgINO2
Reverse for 3’ NCR of CgINO2
Forward for 5’ NCR of CgHIS3
Reverse for 5’ NCR of CgHIS3
Check insertion of pEB13 (ino4∆)
Check insertion of pEB19 (ino1∆)
Check insertion of pRS306-his3∆
Check insertion of pRS306-ino2∆
Reverse for primers EBO24, EBO27,
and TRO623
Check insertion of pCgopi1∆
Reverse primer for TRO614

Table 3. Plasmids used in this study.
Plasmid
description
pRS306-ino2∆
CgINO2 knockout
CgINO2 reintegration
pRS306-CgINO2
pEB19
CgINO1 knockout
pEB21
CgINO1 reintegration
pEB13
CgINO4 knockout
pEB17
CgINO4 reintegration
pCgOPI1
contains CgOPI1
pCgopi1∆
Cgopi1∆
pRS306-his3∆
CgHIS3 knockout
pGRB2.1
ScURA3 vector
pAG25
NAT1 cassette
pEB48
tetO::HOP1::CgOPI1
pINTG4
tetR::GAL4AD
pRS306
Shuttle vector

type
integrating
integrating
integrating
integrating
integrating
integrating
episomal
integrating
integrating
episomal
PCR template
Integrating
Integrating
Integrating
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restriction site

SnaBI
SnaBI
Nru1
Nru1
Pml1
Pml1

BglII

Reference
This study
This study
This study
This study
This study
This study
This study
This study
This study
[72]
[73]

This study
[75]
[82]

Appendix 2: Figures

Figure 1. The Inositol Regulon in S. cerevisiae.
The inositol regulon in S. cerevisiae controls transcription of phospholipid
biosynthetic genes like ScINO1 in response to the level of extracellular inositol.
(A) The ScIno2p-ScIno4p heterodimer activates transcription of ScINO1 and
other target genes in the absence of extracellular inositol. ScIno2p-ScIno4p binds
the upstream activating sequence for inositol regulation (UASINO) present in the
promoters of genes like ScINO1. (B) In the presence of extracellular inositol
ScOpi1p binds to ScIno2p and prevents it from activating transcription of ScINO1
and other targets.
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Figure 2. Inositol Auxotrophy of Cgino1, Cgino2, and Cgino4.
The CgINO1, CgINO2, and CgINO4 genes are all involved in de novo inositol
biosynthesis, like their S. cerevisiae homologuess. The Cgino1∆, Cgino2∆, and
Cgino4∆ mutants and their respective reconstituted strains (along with the wildtype control) were streaked onto inositol free media supplemented with 0 or
75µM inositol, and grown at 30˚C for 3 days.
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Figure 3. CgINO1 Expression in Mutants.
CgINO2 and CgINO4 are required to express CgINO1 in the absence of
exogenous inositol. Northern blotting was used to assess the expression of
CgINO1 in wild-type (WT), mutant, and reconstituted strains in the presence or
absence of exogenous inositol. CgACT1 was used as a loading control. Strains
were grown overnight at 30˚C in inositol-free medium supplemented with 75µM
inositol, washed with water, and resupended in inositol-free media containing
either 0 or 75µM inositol, after which the cultures were incubated with shaking
for 6 hours before collecting total RNA for Northern blotting.
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Figure 4. Diagram of molecular technique used to show that CgOPI1 is essential.
(A) CgOPI1 was expressed episomally from a single-copy (CEN/ARS) vector
carrying a URA3 marker (pCgOPI1). (B) The chromosomal copy was then
disrupted with a Cgopi1∆ disruption cassette by homologous recombination. (C )
The resulting Cgopi1∆::NAT1 pCgOPI1 strain was then streaked on 5-FOA
medium to select for cells that lost the pCgOPI1 plasmid. Those which did loose
the plasmid could not grow because the chromosomal copy was missing as well
and CgOPI1 is essential.
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Figure 5. The CgOPI1 gene is essential.
Wild-type (WT) and Cgopi1∆ strains carrying CgOPI1 on a URA3 plasmid
(pCgOPI1) were grown for 3 days on media +/- 5-FOA at 30˚C.

Figure 6. A CgOPI1-CgINO2 double knockout rescues growth.
The Cgopi1∆ mutant’s viability defect is dependent on the CgINO2
transcriptional activator. The wild-type (WT), Cgopi1∆, Cgino2∆, and Cgopi1∆
Cgino2∆ strains containing the pCgOPI1 plasmid (URA3-based) were streaked
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onto synthetic media plates ± 5-FOA. The WT strain containing the empty vector
was included as a control.

Figure 7. CgOpi1p is a transcriptional repressor of CgINO1.
The promoter of the chromosomal copy of CgOPI1 was replaced with the
doxycycline-repressible tetO::HOP1 promoter. (A) Expression of CgOPI1,
CgINO1, and CgACT1 (loading control) were tested by Northern blotting in the
presence and absence of doxycycline. Cells were grown to saturation overnight in
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synthetic medium (contains ~11 µM inositol) lacking doxycycline, washed with
water, and then resupended in fresh synthetic media containing 0 or 10 µg/ml
doxycycline and grown for ~6 hours at 30˚C with shaking at which time samples
were taken for Northern blotting. (B) Cells were grown on plates containing 0 or
10µg/ml doxycycline to confirm that loss of CgOPI1 expression decreased
viability. Two different transformants were tested for doxycycline repressible
promoter.
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Figure 8. Two-step gene deletion method for disrupting CgINO1 in C. glabrata.
The pRS306-ino1∆ plasmid was cut with NruI and transformed into the BG2
strain (ura3∆) and selected on SC-ura medium. The resulting transformant was
then grown in YPD and plated on 5-FOA medium to select for strains where the
integrated plasmid had recombined out of the chromosome and was lost. PCR
was used to determine which allele (wild-type or disruptant) was left behind. The
CgINO1 ORF is shown in gray. The 500 base-pair 5’ and 3’-non-coding regions
(NCRs) flanking the ORF are labeled 5 and 3, respectively. The URA3 gene is
labeled U.
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Mut2+

Figure 9. Expression of CgOPI3 and CgCHO1.
A. Northern blot measuring gene expression of CgOPI3 and CgCHO1 by wild
type and two strains having the CgOPI1 gene fused to the tet system. This was
measured in the presence and absence of 10µg/ml doxycycline. B. Quantification
of northern blot analysis normalized against CgACT1. Series 1 corresponds to
CgCHO1 and Series 2 corresponds to CgOPI3.
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Chapter III
Additional Work in Candida glabrata
Designing Conditional Mutants in Candida glabrata
There are several vectors that are utilized in yeast to conditionally control gene
expression. One such vector contains the promoter of the MtII gene from C. glabrata,
which is induced in the presence of copper. When the MtII promoter was fused to the
lacZ gene of Escherichia coli and transformed into C. glabrata, β-galactosidase activity
was detected with increasing concentrations of copper (CuSO4) [76].
A vector carrying this inducible-conditional promoter (Figure A.5) was used to
control expression of the CgOPI1 gene, which is essential for the viability of the
organism. Although a lack of CuSO4 in the medium led to a lack of detectable
expression of CgOPI1 from the MtII promoter as measured by Northern blotting (Figure
A.6A), the conditional mutant remained viable (Figures A.6B and A.6C). This promoter
did serve to show that CgOPI1 controls CgINO1 expression, since in the absence of
detectable CgOPI1 (0 µM CuSO4), the CgINO1 gene was overexpressed (Figure A.6A).
In as little as 20µM CuSO4, no expression of CgINO1 was detected, while CgOPI1 was
strongly expressed (Figure A.6A).
The above analysis was performed using the MTII promoter on an episomal
plasmid, pEB9 (Figure A.5). It was hypothesized that the episomal plasmid, although
centromeric, may be present in multiple copies per cell and may cause enough expression
of CgOPI1 to explain the strain’s viability even in the absence of extra CuSO4. CgOPI1
expression level was not detectable by Northern blotting, but since the cells were viable,
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CgOPI1 was believed to be present based on the fact that a complete CgOPI1 deletion
mutant is inviable (see chapter 2). Therefore, the MTII promoter-CgOPI1 construct was
subcloned into an integrating vector and integrated into the strain at the MTII locus. This
resulted in several transformants, some of which failed to grow on plates in the absence
of CuSO4, and others did grow in the absence of CuSO4 (data not shown). It was
hypothesized that the strains that did grow had multiple copies of the plasmid integrated
and the strains that did not grow had only one copy. There are three virtually identical
MTII genes so the multiple integrations seemed possible. However, Southern blot
analysis was inclusive, thus we do not know why some strains grew and others did not.
In order to confirm the essential nature of the gene as well as to obtain a useable
conditional mutant of CgOPI1, we needed to utilize a vector that would provide a tight
enough shutoff of the gene to eliminate its viability. In Candida albicans, the MET3
promoter can be used to repress gene expression in the presence of cysteine and/or
methionine [84]. Since C. glabrata has a homologue of this gene, it was hypothesized
that this could serve as a conditional promoter in this organism. Again, the viability of a
strain of C. glabrata containing this vector was not diminished. When a northern blot
experiment was performed, the results were ambiguous, leading to the conclusion that the
C. glabrata homologue of MET3 does not make an efficient conditional promoter (all
data not shown).
Sufficient control of CgOPI1 expression was eventually obtained using the
doxycycline-repressible system, indicating that it is probably the most effective
conditional promoter currently available for C. glabrata (See chapter 2 for details).
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CgCHO1
Genes involved in phospholipid biosynthesis are beginning to be studied in
pathogens in the context of virulence. In Mycobacterium tuberculosis, a mutant of the
ino1 gene was attenuated for virulence. It was quickly cleared from murine macrophages
in one experiment and unable to cause mortality in mice in another [85]. In Candida
albicans, the PS synthase-encoding gene, CHO1, has been implicated in virulence, as
cho1/cho1 mutants are avirulent in mice compared to the wild type. A knockout of
both genes responsible for PS decarboxylase, psd1/ psd1 and psd2/psd2 also
resulted in reduced virulence (Reynolds and Chen, unpublished data).
In order to see the phenotype of the Cgcho1 mutant, this gene was disrupted in
Candida glabrata. The gene was initially thought to be essential because it was not
possible to obtain mutants using the two-step gene deletion approach. Therefore, the
Cgcho1 mutant was constructed by the same technique used for the Cgopi1 mutant,
which is depicted in figure 4. This Cgcho1 mutant carrying the pEB41 plasmid could
not grow on medium containing 5-FOA unless the media was supplemented with 5mM
concentrations of ethanolamine or choline. However, even in 5mM ethanolamine and
choline, cells grew poorly and unexpectedly could not be subcultured to a new plate
containing ethanolamine or choline, suggesting that in some way the Cgcho1∆ mutant
was very sick (data not shown). In addition, these strains cannot be recovered from the 80˚C freezer. Only a strain carrying CgCHO1 on the p41 plasmid could be recovered
from the -80˚C freezer. In order to clear this up CgCHO1 was expressed from the MTII
promoter which was integrated into the genome at the CgCHO1 locus using plasmid
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pEB51. This was done by transforming the strain carrying pEB41 and Cgopi1::NAT1
with pEB51, and then selecting on 5-FOA. This strain could not grow in the absence of
CuSO4 without exogenous ethanolamine and/or choline (Figure A.7). However, it grew
very poorly in the presence of 5mM ethanolamine and choline in the absence of CuSO4,
and it was very poorly subcultured to a new plate containing 5 mM ethanolamine and
choline, but not CuSO4. This strain grew much better when plated on media containing
CuSO4. (Figure A.8).
In S. cerevisiae, respiratory deficiency is correlated with increased levels of
CHO1 transcript. PE is a major component of mitochondrial membranes, and it is
necessary that cells synthesize it in order to grow on nonfermentable carbon sources.
The cho1 mutant as well as psd1 and psd1psd2 mutants in S. cerevisiae are more
likely to form petites, or respiratory deficient cells [86]. Respiratory function was also
affected in cho1, psd1, and psd1psd2 mutants of the non-petite-forming yeast, C.
albicans (Reynolds and Chen, unpublished data). Since C. glabrata and S. cerevisiae can
both form petites, the mitochondrial activity of Cgcho1 mutants was observed using
fluorescence microscopy with the mitochondria-staining fluorophore, Mito-tracker. This
also yielded equivocal results; there was clearly a difference between the wild type and
the CgCHO1 mutant, but the mutant fluoresced more than expected (Figure A.9). In an
attempt to understand these observations, petite mutants of C. glabrata were created, and
these failed to fluoresce when stained with Mito-tracker (data not shown). The Cgcho1∆
mutant clearly has some respiratory activity, but it is not clear in what way it is defective.
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Figure A. 1. Relationships among various yeast species.
This figure is from the website http://cbi.labri.fr/Genolevures/. It is based on the
combined results from multigene concatenation and supertree analyses performed
by Fitzpatrick, et al. 2006 [87].
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Figure A. 3. The inositol regulon in S. cerevisiae.
The inositol regulon in S. cerevisiae controls transcription of phospholipid
biosynthetic genes like ScINO1 in response to the level of extracellular inositol.
(A) The ScIno2p-ScIno4p heterodimer activates transcription of ScINO1 and
other target genes in the absence of extracellular inositol. ScIno2p-ScIno4p binds
the upstream activating sequence for inositol regulation (UASINO) present in the
promoters of genes like ScINO1. (B) In the presence of extracellular inositol
ScOpi1p binds to ScIno2p and prevents it from activating transcription of ScINO1
and other targets.
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Figure A. 4. ClustalW analysis.
A.) ClustalW 2.0.10 multiple sequence alignment comparing Opi1p homologues
of S. cerevisiae (S.C.), C. glabrata (C.G.), Y. lipolytica (Y.L.), and C. albicans
(C.A.). Asterisk represents conservation among all four species. Various
domains represented by different colors. Blue: Opi1-Sin3 interaction domain.
Gold: PA-binding domain. Red: Leucine zipper. Green: FFAT. Purple:
Polyglutamine Tract. Orange: Activator Interaction Domain.
B.) Same as 3A, but comparing only S. cerevisiae and C. glabrata.
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MtII
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Sci1
Xho1
Sal1

1676 Nae1
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2004 Kpn1
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2250 SnaB1
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SacII
EcoICR1
Sac1

CgOPI1 ORF
~1.5 kb

Figure A. 5. Plasmid initially used to create MtII-CgOPI1 fusion.
pEB9 is an episomal plasmid that was transformed into a strain containing the
CgOPI1 gene on another plasmid with a URA3 marker. The chromosomal
CgOPI1 was replaced with a nourseothricin-resistance cassette. The plasmids
used for integrating MtII-CgOPI1 and MtII-CgCHO1 fusions (pEB37 and pEB51,
respectively) are similar to this one but lack the C. glabrata CEN/ARS region.
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Figure A. 6. CgOPI1 with MtII promoter integrated into the chromosome.
A.) Northern Blot analysis of the expression of CgOPI1 and CgINO1 in the
presence of varying concentrations of CuSO4. B.) Strains with CgOPI1-MtII
construct grown in SC liquid media in the absence (top) and presence (bottom) of
50 mM CuSO4. Strains are in order from left to right Cg1 (WT), EBCg049-3,
EBCg049-8, EBCg049-10, EBCg049-11, EBCg049-12. C.) CgOPI1-MtII
constructs grown on SC solid media in the absence (left) and presence (right) of
50 mM CuSO4.
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A

B

EBCg045 C

EBCg035

EBCg045 B
Figure A. 7. CgCHO1 mutant is an ethanolamine and choline auxotroph.
Plated on SC media without CuSO4. EBCg045 B and C are two isolates that
carry integrating plasmid, pEB51, which has CgCHO1 fused to the MtII
promoter. A.) 0 µm ethanolamine and 0µm choline. B.) 5µm ethanolamine and
5µm choline.
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A

B

EBCg044 C

EBCg044 B

WT
Figure A. 8. MtII promoter controls expression of CgCHO1
.

C. glabrata strain containing integrating plasmid pEB51 carrying the MtII
promoter fused to CgCHO1 along with CgCHO1 on an episomal plasmid, pEB41,
containing the URA3 gene. Plated on 5-FOA. A.) 0µm CuSO4. B.) 50µm CuSO4.
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A

B

Figure A. 9. Fluorescence microscopy of cells stained with Mito-tracker.
A.) Cg1 wild-type cells. B.) Cgcho1 mutant.
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Table 4. Plasmids used for data in Chapter III.

Plasmids
pEB9

Type
episomal

pEB37
pEB41

integrating—Sma1
Episomal

pEB51

integrating

Description
MtII-CgOPI1, HIS3,
CgCEN/ARS, AmpR
MtII-CgOPI1, HIS3, AmpR
CgCEN/ARS, AmpR, URA3,
CgCHO1 ORF + 5’,3’ NCRs
MtIICgCHO1, HIS3, AmpR

Table 5. Strains used for data in Chapter III.
Strain
Genotype
EBCg044
ura3::Tn903 NeoR, his3, pEB41, pEB51,
CgCHO1::NatR
EBCg045
Ura3::Tn903 NeoR, his3, CgCHO1::NatR, pEB51
EBCG035
Ura3::Tn903 NeoR, his3, pEB41, CgCHO1::NatR
EBCg049
Ura3::Tn903 NeoR, his3, pEB37, CgOPI1::NatR,
pCgOPI1—URA3
EBCg039-42
Petite mutants
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